Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases

Vaccine

Volumn 26, Issue 2, 2008, Pages 241-249

  Fifis, Theodora ^a,b   Lam, Irene ^a,b   Lin, Doris ^a   Malcontenti Wilson, Cathy ^a   Christophi, Christopher ^a   Loveland, Bruce ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Cytokines; Immunosuppression; Tumor immunity; Vaccination

Indexed keywords

ADJUVANT; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; CANCER VACCINES; COLORECTAL NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERFERON TYPE II; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED CBA; TUMOR CELLS, CULTURED;

EID: 37449014526     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.068     Document Type: Article

References (52)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics. CA Cancer J Clin 49 1 31 (1999) 8-31
2. Cromheecke M., de Jong K.P., and Hoekstra H.J. Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 25 5 (1999) 451-463
3. Steele Jr. G., and Ravikumar T.S. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 210 2 (1989) 127-138
4. Liu L.X., Zhang W.H., and Jiang H.C. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 9 2 (2003) 193-200
5. Ruers T., and Bleichrodt R.P. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38 7 (2002) 1023-1033
6. Biasco G., and Gallerani E. Treatment of liver metastases from colorectal cancer: what is the best approach today?. Dig Liver Dis 33 5 (2001) 438-444
7. Allen P.J., and Coit D.G. The surgical management of metastatic melanoma. Ann Surg Oncol 9 8 (2002) 762-770
8. Abdalla E.K., Vauthey J.N., Ellis L.M., Ellis V., Pollock R., Broglio K.R., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239 6 (2004) 818-825 [discussion 825-817]
9. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 49 4 (1999) 231-255
10. Hanna Jr. M.G., Hoover Jr. H.C., Vermorken J.B., Harris J.E., and Pinedo H.M. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19 17-19 (2001) 2576-2582
11. Mazzaferro V., Coppa J., Carrabba M.G., Rivoltini L., Schiavo M., Regalia E., et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9 9 (2003) 3235-3245
12. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12 7 Pt 2 (2006) 2353s-2358s
13. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 8 (1998) 2825-2833
14. Prasad S.J., Farrand K.J., Matthews S.A., Chang J.H., McHugh R.S., and Ronchese F. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+ CD25+ regulatory T cells. J Immunol 174 1 (2005) 90-98
15. O'Rourke M.G., Johnson M., Lanagan C., See J., Yang J., Bell J.R., et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 52 6 (2003) 387-395
16. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 5594 (2002) 850-854
17. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99 25 (2002) 16168-16173
18. Kershaw M.H., Jackson J.T., Haynes N.M., Teng M.W., Moeller M., Hayakawa Y., et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 173 3 (2004) 2143-2150
19. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2 10 (2001) 962-970
20. Lau Y.F., Deliyannis G., Zeng W., Mansell A., Jackson D.C., and Brown L.E. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 18 12 (2006) 1801-1813
21. Tacken P.J., Torensma R., and Figdor C.G. Targeting antigens to dendritic cells in vivo. Immunobiology 211 6-8 (2006) 599-608
22. Heurtault B., Thomann J.S., Jedrzejewska J., Wels W.S., Schuber F., and Frisch B. Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvants. J Liposome Res 16 3 (2006) 205-213
23. Sanders M.T., Brown L.E., Deliyannis G., and Pearse M.J. ISCOM-based vaccines: the second decade. Immunol Cell Biol 83 2 (2005) 119-128
24. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 5 (2004) 3148-3154
25. Breloer M., Fleischer B., and von Bonin A. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J Immunol 162 6 (1999) 3141-3147
26. Kuruppu D., Christophi C., Bertram J.F., and O'Brien P.E. Characterization of an animal model of hepatic metastasis. J Gastroenterol Hepatol 11 1 (1996) 26-32
27. Stoscheck C.M. Increased uniformity in the response of the coomassie blue G protein assay to different proteins. Anal Biochem 184 1 (1990) 111-116
28. Miyahira Y., Murata K., Rodriguez D., Rodriguez J.R., Esteban M., Rodrigues M.M., et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 181 1 (1995) 45-54
29. Malcontenti-Wilson C., Muralidharan V., Skinner S., Christophi C., Sherris D., and O'Brien P.E. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7 4 (2001) 1052-1060
30. Jiang Z., Xu M., Savas L., LeClair P., and Banner B.F. Invariant chain expression in colon neoplasms. Virchows Arch 435 1 (1999) 32-36
31. Chaux P., Moutet M., Faivre J., Martin F., and Martin M. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74 5 (1996) 975-983
32. Atkins D., Breuckmann A., and Schmahl G.E. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 109 2 (2004) 265-273
33. Araibi E.H., Marchetti B., Ashrafi G.H., and Campo M.S. Downregulation of major histocompatibility complex class I in bovine papillomas. J Gen Virol 85 Pt 10 (2004) 2809-2814
34. Muris J.J., Meijer C.J., and Cillessen S.A. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 18 3 (2004) 589-596
35. Srivastava P.K., DeLeo A.B., and Old L.J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 83 10 (1986) 3407-3411
36. Breloer M., Marti T., Fleischer B., and von Bonin A. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and gp96. Eur J Immunol 28 3 (1998) 1016-1021
37. Ikeda H., Old L.J., and Schreiber R.D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13 2 (2002) 95-109
38. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7 (2007) 4
39. Rouse B.T., and Regulatory. T cells in health and disease. J Intern Med 262 1 (2007) 78-95
40. Appay V., Jandus C., and Voelter V. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 177 3 (2006) 1670-1678
41. Rosenberg S.A., Sherry R.M., and Morton K.E. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175 9 (2005) 6169-6176
42. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 9 (2004) 909-915
43. Barnett B., Kryczek I., Cheng P., Zou W., Curiel T.J., and Regulatory. T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54 6 (2005) 369-377
44. Serafini P., De Santo C., and Marigo I. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53 2 (2004) 64-72
45. Dannull J., Su Z., and Rizzieri D. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 12 (2005) 3623-3633
46. Liyanage U.K., Moore T.T., and Joo H.G. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169 5 (2002) 2756-2761
47. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 4 (2005) 345-352
48. Yu P., and Fu Y.X. Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest 86 3 (2006) 231-245
49. Prins R.M., Scott G.P., Merchant R.E., and Graf M.R. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol Immunother 51 4 (2002) 190-199
50. Nishikawa H., Kato T., and Tanida K. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100 19 (2003) 10902-10906
51. Parmiani G., Sensi M., Castelli C., Rivoltini L., and Anichini A. T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immun 2 (2002) 6
52. Pollak H., Brunner H., and Kempf P. Incurable gastric malignomas with 5-year remission. Fortschr Med 92 13 (1974) 559